REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	$ 29,511	$ 32,765
Contract receivables, current	900		$ 900
Contract receivables, noncurrent	3,400		3,300
Current portion of deferred revenue, and other	9,200		9,600
Contract liabilities, revenue recognized	700
Contract liabilities, increase due to additional deferred sales	$ 400
Average term of underlying contracts	6
Capitalized contract costs	$ 2,500		$ 2,500
Capitalized contract costs, amortization	200
Capitalized contract costs during the period	300
Core companion animal
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	24,716	26,819
Point of Care laboratory revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	15,961	13,641
Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	12,317	10,821
Sales-type leases
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,742	1,538
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,528	811
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	374	471
Point of Care imaging revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	5,410	5,972
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,546	5,137
Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	562	556
Operating type leases and other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	302	279
Other CCA revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,345	7,206
Other pharmaceuticals, vaccines and diagnostic tests
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,246	7,109
Research and development, license and royalty revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	99	97
Other vaccines and pharmaceuticals
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,795	5,946
Contract manufacturing
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,666	5,791
License, research and development
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	$ 129	$ 155